Kymera Therapeutics vs Protalix BioTherapeutics
KYMR and PLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KYMR and PLX compare
Kymera Therapeutics is the larger company, worth 45 times as much as Protalix BioTherapeutics ($10.4B against $232M).
Kymera Therapeutics grew revenue faster over the last twelve months (134% versus 30.1% for Protalix BioTherapeutics).
Protalix BioTherapeutics keeps more of each dollar of sales as profit, with a net margin of 23.5% compared with −342% at Kymera Therapeutics.
Protalix BioTherapeutics scores higher on the StockData Score (16 against 9 for Kymera Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KYMR | PLX |
|---|---|---|
| Size and price | ||
| Market cap | $10.4B | $232M |
| Share price | $121.52 | $2.88 |
| Change, 1 year | 87.1% | 54.8% |
| Change, 5 years | 126% | 191% |
| Beta (5Y) | 0.59 | 1.40 |
| Employees | 238 | 226 |
| StockData Score | ||
| Total score | 9 | 16 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 12.5× |
| P/S | 101× | 2.9× (better) |
| P/B | 6.4× | 3.2× (better) |
| EV/EBITDA | – | 8.8× |
| P/FCF | – | 30.3× |
| FCF yield | −2.8% | 3.3% (better) |
| Fair value | $37.15 | $5.38 |
| Margin of safety | −227% | 46.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 134% (better) | 30.1% |
| Revenue growth, 5Y average | 2.9% (better) | −3.5% |
| Net income growth (TTM) | – | 202% |
| EPS growth (TTM) | – | 475% |
| Profitability | ||
| Gross margin | 0.00% | 69.2% (better) |
| Operating margin | −396% | 28.9% (better) |
| Net margin | −342% | 23.5% (better) |
| FCF margin | −283% | 9.5% (better) |
| Return on equity | −27.3% | 31.2% (better) |
| Return on invested capital | −59.0% | 49.5% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 11.13 (better) | 2.94 |
| Altman Z-score | 39.62 (better) | 5.67 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 114% | 17.9% |
| Held by insiders | 38.3% | 3.8% |
| Insider net buying, 12 months | −$301M | $101K (better) |
| Short interest, % of float | 16.0% | 4.5% |
Go deeper
- KYMR stock overview
- KYMR income statement
- KYMR valuation and score
- PLX stock overview
- PLX income statement
- PLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.